C07K 16/2812
Against cd4
Official title: {against CD4}
C07K16/2812 (Against cd4) appears on 358 US grants and 541 published applications in this corpus.
Search patents in C07K- Granted patents
- 358
- Published applications
- 541
- Assignees
- 276
- Inventors
- 972
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 3 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 3 | 0 |
| 1996 | 7 | 0 |
| 1997 | 11 | 0 |
| 1998 | 8 | 0 |
| 1999 | 18 | 0 |
| 2000 | 14 | 0 |
| 2001 | 9 | 3 |
| 2002 | 8 | 16 |
| 2003 | 7 | 23 |
| 2004 | 10 | 15 |
| 2005 | 9 | 15 |
| 2006 | 4 | 26 |
| 2007 | 8 | 10 |
| 2008 | 6 | 14 |
| 2009 | 8 | 21 |
| 2010 | 7 | 17 |
| 2011 | 6 | 19 |
| 2012 | 10 | 11 |
| 2013 | 11 | 23 |
| 2014 | 12 | 17 |
| 2015 | 8 | 16 |
| 2016 | 11 | 17 |
| 2017 | 14 | 24 |
| 2018 | 15 | 28 |
| 2019 | 25 | 35 |
| 2020 | 11 | 30 |
| 2021 | 19 | 27 |
| 2022 | 13 | 40 |
| 2023 | 12 | 25 |
| 2024 | 19 | 33 |
| 2025 | 17 | 14 |
| 2026 | 8 | 22 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Chimeric antigen receptors (CARs) targeting hematologic malignancies, compositions and methods of use thereof15 Sep 2026US 12,735,471 B2iCell Gene Therapeutics Inc.
- Compositions and methods for inhibiting T cell exhaustion8 Sep 2026US 12,729,245 B2The Board of Trustees of the Leland Stanford Junior University
- Methods and compositions for engineering CD4-deficient CAR T cells and anti-CD4 CAR T cells and uses thereof11 Aug 2026US 12,703,735 B2Seattle Children's Hospital
- Modular platform for targeted therapeutics30 Jun 2026US 12,668,643 B2Ramot at Tel-Aviv University Ltd.
- T cell receptors and methods of use thereof12 May 2026US 12,624,082 B2University Health Network
- Heterodimeric Antibodies, Uses in Therapeutic Applications, and Compositions Related Thereto1 Oct 2026US 2026/0297211 A1
- Nanoparticle compositions and uses thereof for reactivation of latent hiv27 Aug 2026US 2026/0248880 A1The Trustees of the University of Pennsylvania
- Cd4 + and cd8 + single positive t cells and compositions and methods for generating the same20 Aug 2026US 2026/0242728 A1Clade Therpaeutics, Inc.
- Pseudotyped viral particles for targeting tcr-expressing cells6 Aug 2026US 2026/0226500 A1Regeneron Pharmaceuticals, Inc.
- Compositions and methods of use thereof for increasing immune responses16 Jul 2026US 2026/0199254 A1University of Georgia Research Foundation, Inc.
Most cited
By later US patents
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies1,680US 5,633,425 AGenPharm International, Inc. · 1997
- Transgenic non-human animals for producing heterologous antibodies1,604US 5,625,126 AGenPharm International, Inc. · 1997
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,541US 5,661,016 AGenPharm International, Inc. · 1997